Global Theranostics Market
Drivers:-
Development of novel companion
diagnostic tests to be used with available treatment options is expected to
boost the global Theranostics
Market growth over the forecast period. Leading manufacturers are engaged
in introduction of novel companion diagnostic tests in market. For instance,
Illumina, Inc. announced launch of the U.S. Food & Drug Administration
(FDA) approved extended RAS panel for identification of patients eligible for
treatment of metastatic colorectal cancer with Vectibix (panitumumab) in 2017.
Increasing adoption of companion
diagnostic tests by laboratories is further expected to foster global
theranostics market growth over the forecast period. BloodCenter of Wisconsin's
Diagnostic Laboratories started offering Abbott RealTime IDH1 assay for
patients with acute myeloid leukemia (AML) in July 2018. Moreover, Cancer
Genetics, Inc. started offering FDA approved companion diagnostic Thermo Fisher
Scientific's Oncomine Dx Target - the first Next-Generation Sequencing
(NGS)-based Companion Diagnostic (CDx) test in 2017. Laboratory Corporation of
America Holdings launched OmniSeq Advance in partnership with OmniSeq for tumor
cancers in June 2018.
Partnerships and collaborations
by leading manufacturers to develop innovative companion diagnostics is
expected to foster global theranostics market growth over the forecast period.
For instance, Foundation Medicine, Inc. and Pfizer, Inc. entered into a
partnership for development, regulatory support, and commercialization of
companion diagnostics (CDx) in January 2018. Moreover, Qiagen, Inc., and
Freenome partnered in June 2018, to accelerate the development and
commercialization of Next-Generation Sequencing (NGS) tests to enable precision
medicine in cancer treatment.
Pierre Fabre and Roche have been
working on development of a robust prototype immunohistochemistry assay as a
future companion diagnostic test for W0101 (the drug candidate which they are
developing together) and extended this collaboration in May 2018. Abbott
Laboratories, Inc. collaborated with Celgene Corporation, and Agios
Pharmaceuticals, to develop diagnostic tests on Abbott’s m2000 RealTime system
that identifies certain genomic mutations associated with acute myeloid
leukemia (AML) in 2016. These factors are expected to support global
theranostics market growth over the forecast period.
* The sample copy includes:
Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report
Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2043
Theranostics involves combination
of targeted diagnostic tests with targeted therapy. It is also known as
companion diagnostics, integrated medicine, Dx/Rx partnering, and
pharmacodiagnostics. Implementation of theranostics into the patient care plan
(in case of selected diseases for which diagnostic tests are available along
with respective therapy) may turn into personalized therapy, which could further
improve medical outcomes.
Theranostics include use of specific
diagnostic test, which shows a particular molecular target on a tumor or any
other disease causing agent. Any disease pathophysiology involves specific
biological pathways, which are targeted with the help of diagnostic tests.
Diagnostic images of the particular molecule then identifies presence of the
specific mutation or receptors (in case of cancer), which can be targeted with
the help of therapeutic agents. This approach avoids trial and error treatment
and could be used to offer patient specific treatment at the right time.
Accurate dose calibration and precisely targeted approach could highly be
useful in management of chronic diseases such as cancer.
For instance, neuro endocrine
tumors can be diagnosed to assess extent of disease via PET-CT (Positron
Emission Tomography – Computer Tomography) using Ga-68 DOTATOC (a radioactive
positron emitter). Ga-68 targets somatostatin receptor (SSTR2) on the tumor
cell membrane, and is injected through vein, which travels and binds to the
SSTR2 indication the presence of tumor on PET scan. Furthermore, Ga-68 can be
replaced by a therapeutic agent to target the tumor.
However, improperly defined
regulations for these tests coupled with inadequate reimbursement facilities
are expected to hamper growth of the global theranostics market over the
forecast period.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/theranostics-market-2043
Global Theranostics Market
Regional Insights:-
North America is expected to
witness significant growth in the global theranostics market over the forecast
period. Presence of leading manufacturers, collaborations, robust research, and
development activities, and increasing adoption of companion diagnostics is
expected to support global theranostics market growth over the forecast period.
Biocartis Group NV and Amgen, Inc. partnered to develop companion diagnostic
test for Amgen's drug Vectibix (panitumumab) in 2017. For instance, Genome
Canada launched a national initiative for clinical implementation of precision
health in June 2018, which would ultimately impact global theranostics market growth
over the forecast period.
Asia Pacific theranostics market
is expected to witness significant growth over the forecast period, owing to
collaborations in the region by global organizations and increasing awareness
regarding companion diagnostics. For instance, Qiagen collaborated with Japan
based clinical lab testing company, SRL, Inc. for introduction of new companion
diagnostics with new drug approvals in August 2018.
Key players of Global
Theranostics Market:-
Key players operating in the
global theranostics market include Thermo Fisher Scientific, Inc., Beckman
Coulter, Inc., Focus Diagnostics, AmeriPath, Inc., Illumina, Inc., F.Hoffmann
LA-Roche Ltd., Qiagen NV, Myriad Genetics, Inc., Agilent Technologies, Abbott
Laboratories, Foundation Medicine, Inc., and Oxford Cancer Biomarkers, Ltd.
Key Development:-
In 2018, THERADIAG, a company
specialized in vitro diagnostics and theranostics entered into partnership
agreement with Biogaran to supply its Lisa Tracker kits for Biogaran biosimilar
monitoring.
In 2018, Novartis AG, entered
into an agreement with Endocyte, a US-based Biopharmaceutical Company which
develops targeted therapeutics for cancer treatment.
In 2018 RadioMedix Inc. and AREVA
Med LLC, announced the Phase 1 trial for AlphaMedixTM in patients with
somatostatin receptor positive neuroendocrine tumors in the U.S. AlphaMedixTM
is composed of a somatostatin (SST) analogue radiolabeled with 212Pb, an
isotope used for Targeted Alpha-emitter Therapy (TAT).
In 2016, avant diagnostics and
Amarantus Diagnostics have signed a letter of intent to acquire theranostics
health, a protein analysis service provider.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2043
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment